One known method of drug therapy to treat UC is administration of aminosalicylates. Aminosalicylates include 5-aminosalicylic acid (5-ASA), salts thereof, and pro-drugs that release 5-aminosalicyclic acid, or salts thereof, in vivo. Pro-drugs that release 5-aminosalicylic acid, or salts thereof, in vivo include, but are not limited to: olsalazine, balsalazide, and sulfasalazine. Aminosalicylates may be administered orally, through an enema, or in a suppository. Most people with mild or moderate ulcerative colitis are treated with aminosalicylates drugs first. The aminosalicylates also used in cases of relapse and to maintain remission. ASACOL® is a product comprising the aminosalicylate, 5-aminosalicylic acid or mesalamine. ASACOL® is effective in treating patients with mild to moderate ulcerative colitis. Its effectiveness also extends to the maintenance of remission for prolonged periods. The current recommended dose of orally delivered ASACOL® for active disease is two 400-mg tablets three times daily for a total of 2.4 g/day (grams per day) for the treatment of mild to moderate UC. If the patient does not respond to ASACOL®, then alternatives, such as corticosteroids, are considered.
It is discovered herein that wherein the subject is a mammalian male and the UC is moderate, administration of aminosalicylate at doses in an amount to deliver greater than about 2.4 g/day, shows significant improvement in the condition.
 

In one aspect of the present invention there is method of treating moderate ulcerative colitis in a mammalian male subject comprising the step of orally administering to the mammalian male subject an aminosalicylate in an amount to deliver greater than about 2.4 g/day of 5-aminosalicylic acid to the subject. In some embodiments, the step of orally administering an aminosalicylate comprises orally administering an aminosalicylate in an amount to deliver about 4.8 g/day of 5-aminosalicylic acid to said subject. In some embodiments wherein about 4.8 g/day of 5-aminosalicylic acid is delivered to the subject, the aminosalicylate comprises mesalamine or a salt thereof. In some embodiments wherein about 4.8 g/day of 5-aminosalicylic acid is delivered to the subject, the step of orally administering comprises orally administering once per day, twice per day, three times per day, or four times per day. In some embodiments, the aminosalicylate comprises mesalamine or a salt thereof. In certain embodiments, the aminosalicylate comprises mesalamine and further wherein the mesalamine is administered in an amount of about 4.8 g/day. In certain embodiments, the mammalian male subject is a human male. In certain embodiments, the mammalian male subject is less than about 65 years of age. In certain embodiments, the mammalian male subject is a non-smoking subject. In certain embodiments, the mammalian male subject is Caucasian. In certain embodiments, the mammalian male subject is a previous or current steroid user. In some embodiments, the step of orally administering comprises orally administering tablets comprising about 800 milligrams of mesalamine or a salt thereof. In some embodiments wherein tablets comprising about 800 milligrams of mesalamine or a salt thereof are orally administered, the tablets are delayed-release tablets. In some embodiments, the step of orally administering comprises orally administering tablets comprising about 1.2 g mesalamine or a salt thereof. In some embodiments wherein tablets comprising about 1.2 g of mesalamine or a salt thereof are orally administered, the tablets are delayed-release tablets. In some embodiments, the aminosalicylate comprises a component selected from the group consisting of mesalamine, a salt of mesalamine, olsalazine, a salt of olsalazine, balsalazide, a salt of balsalazide, sulfasalazine, a salt of sulfasalazine, or any pharmaceutically acceptable combination thereof. In some embodiments, the step of orally administering comprises orally administering once per day, twice per day, three times per day, or four times per day.

In another aspect of the present invention, there is method of treating moderate ulcerative colitis in a mammalian male subject comprising the step of administering to the mammalian male subject an aminosalicylate in an amount to deliver greater than about 2.4 g/day but less than or equal to about 4.8 g/day of 5-aminosalicylic acid to the subject. In certain embodiments, the step of administering comprises rectal administration. In some embodiments, the step of administering an aminosalicylate comprises administering an aminosalicylate in an amount to deliver about 4.8 g/day of 5-aminosalicylic acid to the subject. In some embodiments wherein about 4.8 g/day of 5-aminosalicylic acid is delivered to the subject, the aminosalicylate comprises mesalamine or a salt thereof. In some embodiments wherein about 4.8 g/day of 5-aminosalicylic acid is delivered to the subject, the step of administering comprises administering once per day, twice per day, three times per day, or four times per day. In some embodiments, the aminosalicylate comprises mesalamine or a salt thereof. In some embodiments, the aminosalicylate comprises mesalamine and further wherein the mesalamine is administered in an amount of about 4.8 g/day. In certain embodiments, the mammalian male subject is a human male. In certain embodiments, the mammalian male subject is less than about 65 years of age. In certain embodiments, the mammalian male subject is a non-smoking subject. In certain embodiments, the mammalian male subject is Caucasian. In certain embodiments, the mammalian male subject is a previous or current steroid user. In certain embodiments, the step of administering comprises administering a rectal composition comprising about 800 milligrams or about 1.2 g of mesalamine or a salt thereof. In some embodiments, the rectal composition is an enema. In some embodiments, the rectal composition is a foamed composition. In some embodiments wherein a rectal composition is administered, the rectal composition is a suppository. In some embodiments, the aminosalicylate comprises a component selected from the group consisting of mesalamine, a salt of mesalamine, olsalazine, a salt of olsalazine, balsalazide, a salt of balsalazide, sulfasalazine, a salt of sulfasalazine, or any pharmaceutically acceptable combination thereof. In some embodiments, the step of administering comprises administering once per day, twice per day, three times per day, or four times per day.

The foregoing has outlined the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present invention. 
 

There are also herbal medicines which can very effectively treat colitis & ulcerative colitis. Boswellia is an Ayurvedic  (Indian traditional medicine) herb, used as a natural alternative to drugs. Many studies have found that the effectiveness of Boswellia is similar and even superior to sulfasalazine based prescription drugs. (Source Wikipedia: http://en.wikipedia.org/wiki/Ulcerative_colitis. 

We recommend taking a 4 months course of our Boswellia Serrata Extract.
 
 

Total of 4 bottles-  of Boswellia - 4 Months course - Taken 2 capusles twice a day.
 
 

There are NO ADDITIONAL CHARGES. Packing & Shipping is absolutely FREE. We will deliver direct to your door to reach within 12 days from the date of ordering. A signature will be required at the time of delivery. You can give us your daytime work address or Post Box address if no one will be present at home to receive the shipment during daytime. 
 

Please use the form below to mail us for any information. We will revert back within 10 hours .